Meeting
2023 ASCO Annual Meeting
CD8 cell PET imaging with 89-Zr-crefmirlimab berdoxam (crefmirlimab) in patients with metastatic renal cell carcinoma (mRCC) receiving checkpoint inhibitors (CPIs): Association with response and tissue CD8 expression.
Authors
Sumanta Kumar Pal
City of Hope, Duarte, CA
Sumanta Kumar Pal , Przemyslaw Twardowski , Delphine L. Chen , Evan Thomas Hall , David Hays , Ian Wilson , Kristin Schmiedehausen , Michael Ferris , William Le , Michael A. Postow
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT03802123
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4551)
DOI
10.1200/JCO.2023.41.16_suppl.4551
Abstract #
4551
Poster Bd #
43
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Baseline CD8 lymph node avidity with 89-Zr-crefmirlimab in patients with metastatic renal cell carcinoma and response to IO therapy.
First Author: Peter D. Zang
Poster
2022 ASCO Annual Meeting
A phase I trial to evaluate the biologic effect of CBM588 (Clostridium butyricum) in combination with cabozantinib plus nivolumab for patients with metastatic renal cell carcinoma (mRCC).
First Author: Luis A Meza
Poster
2021 ASCO Annual Meeting
An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer.
First Author: Apostolia Maria Tsimberidou
Poster
2021 Genitourinary Cancers Symposium
Distinct cytokines predict response to immunotherapy and targeted therapy in metastatic renal cell carcinoma (mRCC).
First Author: Alex Chehrazi-Raffle